Risk analysis and assessment based on Sigma metrics and intended use

In order to ensure the quality in clinical laboratories and meet the low risk requirements of patients and clinicians, a risk analysis and assessment model based on Sigma metrics and intended use was constructed, based on which differential sigma performance ( ) expectations of 42 analytes were deve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biochemia Medica 2018-06, Vol.28 (2), p.020707-020707
Hauptverfasser: Xia, Yong, Xue, Hao, Yan, Cunliang, Li, Bowen, Zhang, ShuQiong, Li, Mingyang, Ji, Ling
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 020707
container_issue 2
container_start_page 020707
container_title Biochemia Medica
container_volume 28
creator Xia, Yong
Xue, Hao
Yan, Cunliang
Li, Bowen
Zhang, ShuQiong
Li, Mingyang
Ji, Ling
description In order to ensure the quality in clinical laboratories and meet the low risk requirements of patients and clinicians, a risk analysis and assessment model based on Sigma metrics and intended use was constructed, based on which differential sigma performance ( ) expectations of 42 analytes were developed. Failure mode and effects analysis was applied to produce an analytic risk rating based on three factors, each test of which was graded as follows: 1) Sigma metrics; 2) the severity of harm; 3) intended use. By multiplying the score of Sigma metrics by the score of severity of harm by the score of intended use, each was assigned a typical risk priority number (RPN), with RPN ≤ 25 rated as low risk. Low risk was defined as acceptable standards; the sigma performance expectations were calculated. Among the 42 analytes, tests with ≥ 6, 5 ≤ < 6, 4 ≤ < 5, 3 ≤ < 4, < 3 were 21, 5, 5, 6, and 5, respectively; there were 7 high-risk tests, 8 of them medium risk tests. According to the risk assessment conclusion, 13 tests had sigma performance expectations ≥ 6; 15 test items had sigma performance expectations ≥ 5, while 3 test items had sigma performance expectations ≥ 4; 11 test items had sigma performance expectations ≥ 3. Constructing the risk analysis and assessment model based on Sigma metrics and intended use will help clinical laboratories to identify the high-risk tests more objectively and comprehensively. Such model can also be used to establish the sigma performance expectations and meet the low risk requirements of patients and clinicians.
doi_str_mv 10.11613/BM.2018.020707
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6039164</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2072188408</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-3706c4eb0647d0d943414ce725e46a3e562b14526e874c9a1da09cd6819ed5bd3</originalsourceid><addsrcrecordid>eNpVkUtP3TAQhS1UxHvdXZVlN7mMH7GdDVKB0lYCIUFZW449gCEP6smtxL-vaSgqKx95vjn2zGHsI4cV55rLw-OLlQBuVyDAgNlgO9wqXRtlxYeipYQaWi222S7RA0DTNNZssW0JIIS1YoedXiV6rPzo-2dKVESsPBESDTjOVecJYzWN1XW6G3w14JxTWKg0zjjGUl0T7rPNW98THryee-zm7OvPk-_1-eW3HydfzuugJJ9raUAHhR1oZSLEVknFVUAjGlTaS2y06LhqhEZrVGg9jx7aELXlLcami3KPHS2-T-tuwBjKF7Pv3VNOg8_PbvLJva-M6d7dTb-dBtlyrYpBvRjc5-Af3zUuN5QDFunKThthCv_59cE8_VojzW5IFLDv_YjTmgpmBLdWgS3o4YKGPBFlvH1z5-D-ZuWOL158rVuyKh2f_p_mjf8XjvwDcgaPZw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2072188408</pqid></control><display><type>article</type><title>Risk analysis and assessment based on Sigma metrics and intended use</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Free E-Journal (出版社公開部分のみ)</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Xia, Yong ; Xue, Hao ; Yan, Cunliang ; Li, Bowen ; Zhang, ShuQiong ; Li, Mingyang ; Ji, Ling</creator><creatorcontrib>Xia, Yong ; Xue, Hao ; Yan, Cunliang ; Li, Bowen ; Zhang, ShuQiong ; Li, Mingyang ; Ji, Ling</creatorcontrib><description>In order to ensure the quality in clinical laboratories and meet the low risk requirements of patients and clinicians, a risk analysis and assessment model based on Sigma metrics and intended use was constructed, based on which differential sigma performance ( ) expectations of 42 analytes were developed. Failure mode and effects analysis was applied to produce an analytic risk rating based on three factors, each test of which was graded as follows: 1) Sigma metrics; 2) the severity of harm; 3) intended use. By multiplying the score of Sigma metrics by the score of severity of harm by the score of intended use, each was assigned a typical risk priority number (RPN), with RPN ≤ 25 rated as low risk. Low risk was defined as acceptable standards; the sigma performance expectations were calculated. Among the 42 analytes, tests with ≥ 6, 5 ≤ &lt; 6, 4 ≤ &lt; 5, 3 ≤ &lt; 4, &lt; 3 were 21, 5, 5, 6, and 5, respectively; there were 7 high-risk tests, 8 of them medium risk tests. According to the risk assessment conclusion, 13 tests had sigma performance expectations ≥ 6; 15 test items had sigma performance expectations ≥ 5, while 3 test items had sigma performance expectations ≥ 4; 11 test items had sigma performance expectations ≥ 3. Constructing the risk analysis and assessment model based on Sigma metrics and intended use will help clinical laboratories to identify the high-risk tests more objectively and comprehensively. Such model can also be used to establish the sigma performance expectations and meet the low risk requirements of patients and clinicians.</description><identifier>ISSN: 1330-0962</identifier><identifier>EISSN: 1846-7482</identifier><identifier>DOI: 10.11613/BM.2018.020707</identifier><identifier>PMID: 30022882</identifier><language>eng</language><publisher>Croatia: Medicinska naklada</publisher><subject>Clinical Decision-Making ; failure mode and effects analysis ; Humans ; Original Papers ; risk analysis ; risk assessment ; Risk Assessment - methods ; Sigma metrics ; Six Sigma ; Total Quality Management - methods</subject><ispartof>Biochemia Medica, 2018-06, Vol.28 (2), p.020707-020707</ispartof><rights>Croatian Society of Medical Biochemistry and Laboratory Medicine. 2017 Croatian Society of Medical Biochemistry</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-3706c4eb0647d0d943414ce725e46a3e562b14526e874c9a1da09cd6819ed5bd3</citedby><cites>FETCH-LOGICAL-c431t-3706c4eb0647d0d943414ce725e46a3e562b14526e874c9a1da09cd6819ed5bd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039164/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039164/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30022882$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xia, Yong</creatorcontrib><creatorcontrib>Xue, Hao</creatorcontrib><creatorcontrib>Yan, Cunliang</creatorcontrib><creatorcontrib>Li, Bowen</creatorcontrib><creatorcontrib>Zhang, ShuQiong</creatorcontrib><creatorcontrib>Li, Mingyang</creatorcontrib><creatorcontrib>Ji, Ling</creatorcontrib><title>Risk analysis and assessment based on Sigma metrics and intended use</title><title>Biochemia Medica</title><addtitle>Biochem Med (Zagreb)</addtitle><description>In order to ensure the quality in clinical laboratories and meet the low risk requirements of patients and clinicians, a risk analysis and assessment model based on Sigma metrics and intended use was constructed, based on which differential sigma performance ( ) expectations of 42 analytes were developed. Failure mode and effects analysis was applied to produce an analytic risk rating based on three factors, each test of which was graded as follows: 1) Sigma metrics; 2) the severity of harm; 3) intended use. By multiplying the score of Sigma metrics by the score of severity of harm by the score of intended use, each was assigned a typical risk priority number (RPN), with RPN ≤ 25 rated as low risk. Low risk was defined as acceptable standards; the sigma performance expectations were calculated. Among the 42 analytes, tests with ≥ 6, 5 ≤ &lt; 6, 4 ≤ &lt; 5, 3 ≤ &lt; 4, &lt; 3 were 21, 5, 5, 6, and 5, respectively; there were 7 high-risk tests, 8 of them medium risk tests. According to the risk assessment conclusion, 13 tests had sigma performance expectations ≥ 6; 15 test items had sigma performance expectations ≥ 5, while 3 test items had sigma performance expectations ≥ 4; 11 test items had sigma performance expectations ≥ 3. Constructing the risk analysis and assessment model based on Sigma metrics and intended use will help clinical laboratories to identify the high-risk tests more objectively and comprehensively. Such model can also be used to establish the sigma performance expectations and meet the low risk requirements of patients and clinicians.</description><subject>Clinical Decision-Making</subject><subject>failure mode and effects analysis</subject><subject>Humans</subject><subject>Original Papers</subject><subject>risk analysis</subject><subject>risk assessment</subject><subject>Risk Assessment - methods</subject><subject>Sigma metrics</subject><subject>Six Sigma</subject><subject>Total Quality Management - methods</subject><issn>1330-0962</issn><issn>1846-7482</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUtP3TAQhS1UxHvdXZVlN7mMH7GdDVKB0lYCIUFZW449gCEP6smtxL-vaSgqKx95vjn2zGHsI4cV55rLw-OLlQBuVyDAgNlgO9wqXRtlxYeipYQaWi222S7RA0DTNNZssW0JIIS1YoedXiV6rPzo-2dKVESsPBESDTjOVecJYzWN1XW6G3w14JxTWKg0zjjGUl0T7rPNW98THryee-zm7OvPk-_1-eW3HydfzuugJJ9raUAHhR1oZSLEVknFVUAjGlTaS2y06LhqhEZrVGg9jx7aELXlLcami3KPHS2-T-tuwBjKF7Pv3VNOg8_PbvLJva-M6d7dTb-dBtlyrYpBvRjc5-Af3zUuN5QDFunKThthCv_59cE8_VojzW5IFLDv_YjTmgpmBLdWgS3o4YKGPBFlvH1z5-D-ZuWOL158rVuyKh2f_p_mjf8XjvwDcgaPZw</recordid><startdate>20180615</startdate><enddate>20180615</enddate><creator>Xia, Yong</creator><creator>Xue, Hao</creator><creator>Yan, Cunliang</creator><creator>Li, Bowen</creator><creator>Zhang, ShuQiong</creator><creator>Li, Mingyang</creator><creator>Ji, Ling</creator><general>Medicinska naklada</general><general>Croatian Society of Medical Biochemistry and Laboratory Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>VP8</scope><scope>5PM</scope></search><sort><creationdate>20180615</creationdate><title>Risk analysis and assessment based on Sigma metrics and intended use</title><author>Xia, Yong ; Xue, Hao ; Yan, Cunliang ; Li, Bowen ; Zhang, ShuQiong ; Li, Mingyang ; Ji, Ling</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-3706c4eb0647d0d943414ce725e46a3e562b14526e874c9a1da09cd6819ed5bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Clinical Decision-Making</topic><topic>failure mode and effects analysis</topic><topic>Humans</topic><topic>Original Papers</topic><topic>risk analysis</topic><topic>risk assessment</topic><topic>Risk Assessment - methods</topic><topic>Sigma metrics</topic><topic>Six Sigma</topic><topic>Total Quality Management - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xia, Yong</creatorcontrib><creatorcontrib>Xue, Hao</creatorcontrib><creatorcontrib>Yan, Cunliang</creatorcontrib><creatorcontrib>Li, Bowen</creatorcontrib><creatorcontrib>Zhang, ShuQiong</creatorcontrib><creatorcontrib>Li, Mingyang</creatorcontrib><creatorcontrib>Ji, Ling</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hrcak: Portal of scientific journals of Croatia</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biochemia Medica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xia, Yong</au><au>Xue, Hao</au><au>Yan, Cunliang</au><au>Li, Bowen</au><au>Zhang, ShuQiong</au><au>Li, Mingyang</au><au>Ji, Ling</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk analysis and assessment based on Sigma metrics and intended use</atitle><jtitle>Biochemia Medica</jtitle><addtitle>Biochem Med (Zagreb)</addtitle><date>2018-06-15</date><risdate>2018</risdate><volume>28</volume><issue>2</issue><spage>020707</spage><epage>020707</epage><pages>020707-020707</pages><issn>1330-0962</issn><eissn>1846-7482</eissn><abstract>In order to ensure the quality in clinical laboratories and meet the low risk requirements of patients and clinicians, a risk analysis and assessment model based on Sigma metrics and intended use was constructed, based on which differential sigma performance ( ) expectations of 42 analytes were developed. Failure mode and effects analysis was applied to produce an analytic risk rating based on three factors, each test of which was graded as follows: 1) Sigma metrics; 2) the severity of harm; 3) intended use. By multiplying the score of Sigma metrics by the score of severity of harm by the score of intended use, each was assigned a typical risk priority number (RPN), with RPN ≤ 25 rated as low risk. Low risk was defined as acceptable standards; the sigma performance expectations were calculated. Among the 42 analytes, tests with ≥ 6, 5 ≤ &lt; 6, 4 ≤ &lt; 5, 3 ≤ &lt; 4, &lt; 3 were 21, 5, 5, 6, and 5, respectively; there were 7 high-risk tests, 8 of them medium risk tests. According to the risk assessment conclusion, 13 tests had sigma performance expectations ≥ 6; 15 test items had sigma performance expectations ≥ 5, while 3 test items had sigma performance expectations ≥ 4; 11 test items had sigma performance expectations ≥ 3. Constructing the risk analysis and assessment model based on Sigma metrics and intended use will help clinical laboratories to identify the high-risk tests more objectively and comprehensively. Such model can also be used to establish the sigma performance expectations and meet the low risk requirements of patients and clinicians.</abstract><cop>Croatia</cop><pub>Medicinska naklada</pub><pmid>30022882</pmid><doi>10.11613/BM.2018.020707</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1330-0962
ispartof Biochemia Medica, 2018-06, Vol.28 (2), p.020707-020707
issn 1330-0962
1846-7482
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6039164
source MEDLINE; DOAJ Directory of Open Access Journals; Free E-Journal (出版社公開部分のみ); PubMed Central; PubMed Central Open Access
subjects Clinical Decision-Making
failure mode and effects analysis
Humans
Original Papers
risk analysis
risk assessment
Risk Assessment - methods
Sigma metrics
Six Sigma
Total Quality Management - methods
title Risk analysis and assessment based on Sigma metrics and intended use
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T07%3A05%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20analysis%20and%20assessment%20based%20on%20Sigma%20metrics%20and%20intended%20use&rft.jtitle=Biochemia%20Medica&rft.au=Xia,%20Yong&rft.date=2018-06-15&rft.volume=28&rft.issue=2&rft.spage=020707&rft.epage=020707&rft.pages=020707-020707&rft.issn=1330-0962&rft.eissn=1846-7482&rft_id=info:doi/10.11613/BM.2018.020707&rft_dat=%3Cproquest_pubme%3E2072188408%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2072188408&rft_id=info:pmid/30022882&rfr_iscdi=true